Patent intelligence · US
US 7303881
Antigen delivery compositions and methods of use
Antigen delivery compositions and methods of use
Patent details — US 7303881
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 4, 2007
- Expiration
- Nov 29, 2027
- Applicant
- PDS Biotechnology Corporation
- Claims
- 5
- CPC classes
- A61K, A61K2039/53, A61K2039/55555, A61K2039/585
Quick answer
US 7303881 (Antigen delivery compositions and methods of use) is held by PDS Biotechnology Corporation. Status: granted. Granted Dec 4, 2007. Expires Nov 29, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PDS Biotechnology Corporation
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2039/53, A61K2039/55555, A61K2039/585, A61K2039/6018, A61K2039/6093
More from PDS Biotechnology Corporation
Related pharmaceutical patents in our USPTO index.
-
US 11911359
Stimulation of an immune response by cationic lipids
granted -
US 11911465
Vaccine compositions and methods of use
granted -
US 11904015
Vaccine compositions and methods of use
granted -
US 11801257
Stimulation of an immune response by enantiomers of cationic lipids
granted -
US 11638753
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
granted -
US 11612652
Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
granted -
US 11401306
HPV16 non HLA-restricted t-cell vaccines, compositions and methods of use thereof
granted -
US 10702541
Stimulation of an immune response by enantiomers of cationic lipids
granted
Frequently asked questions
What is US patent 7303881?
US 7303881 (Antigen delivery compositions and methods of use) is held by PDS Biotechnology Corporation. Status: granted. Granted Dec 4, 2007. Expires Nov 29, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7303881?
PDS Biotechnology Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 7303881 expire?
Our index shows an expiration date of Nov 29, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.